Corcept Therapeutics presented pivotal Phase 3 ROSELLA trial data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer at the ASCO 2025 Annual Meeting, with simultaneous publication in The Lancet. The data confirmed a 30 percent reduction in the risk of disease progression (HR: 0.70; p-value: 0.0076), extending median progression-free survival to 6.5 months compared to 5.5 months for nab-paclitaxel alone.
The detailed results also showed that the addition of relacorilant reduced the risk of death by 31 percent, significantly lengthening patients' lives, with a median overall survival of 16.0 months compared to 11.5 months for nab-paclitaxel alone (HR: 0.69; p-value: 0.0121). These benefits were observed across all clinically relevant subgroups.
The combination therapy was well-tolerated, with a safety profile comparable to nab-paclitaxel monotherapy, and notably, a lower incidence of ascites was observed in the relacorilant arm. These compelling results support the regimen's potential to become a new standard of care for patients with platinum-resistant ovarian cancer, and the company is preparing regulatory applications for the U.S. and Europe.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.